The main adaptation conditions of pomalidomide

Pomalidomide (Pomalidomide), as a thalidomide analogue, is mainly used to treat multiple myeloma (MM) and Kaposi's sarcoma worldwide. Its core feature is that it can strengthen the anti-tumor response through immune regulation mechanisms and improve the tumor microenvironment, thereby providing important treatment opportunities for patients with poor previous treatment results. Understanding its specific adaptation conditions can help patients determine whether they are suitable for receiving the drug and avoid misuse or delay in treatment.

In multiple myeloma (MM), pomalidomide is used in adults whose disease has progressed despite at least two lines of treatment. Often these patients have been treated with lenalidomide and proteasome inhibitors but relapsed or relapsed within a short period of time after completing the last treatment. The combined use of pomalidomide and dexamethasone is one of the common late-line options for such patients, providing new treatment possibilities for disease control. Its core value lies in further intervention in drug-resistant MM and improving the survival environment of tumor cells from the perspective of immune regulation.

In addition to myeloma, pomalidomide also has a clear scope of use in the field of Kaposi's sarcoma. Pomalidomide may be used as an additional treatment option for patients with AIDS-related Kaposi's sarcoma whose disease is uncontrolled despite highly active antiretroviral therapy (HAART). In addition, the drug is also suitable for patients with HIV-negative Kaposi's sarcoma, demonstrating its broad application potential in skin tumors and vascular proliferation-related diseases.

It is worth noting that pomalidomide is a drug with potential teratogenic risks, so fertility status and pregnancy risks must be strictly assessed before taking it. Both male and female patients must adhere to strict contraceptive measures during medication, which is one of the core requirements of international regulations.

Reference materials:https://en.wikipedia.org/wiki/Pomalidomide